Breast Cancer Clinical Trial

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

Summary

This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To create a comprehensive registry that includes patient demographics, clinical and histopathological data, blood samples, and tissue specimens from the primary tumor and metastatic sites of patients with metastatic breast cancer to improve our understanding of the mechanisms of tumor metastasis and therapeutic resistance.

II. To conduct genomic studies of paired primary tumors and distant metastatic sites.

III. To conduct genomic studies of paired distant metastatic sites obtained during the course of an individual's disease.

IV. To conduct genomic studies of cell free deoxyribonucleic acid (DNA), circulating tumor cell (CTC) derived DNA, germline DNA, and immune based markers in the peripheral circulation.

SECONDARY OBJECTIVE:

I. To evaluate the concordance between DNA sequencing results obtained from a clinically available assay and those obtained specifically for research purposes.

OUTLINE:

Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed or suspected invasive breast cancer
Radiographic evidence of distant metastatic disease
Clinical or radiographic evidence of disease progression OR presenting with de novo stage IV disease
Available archived tissue from the initial breast primary (formalin fixed paraffin embedded [FFPE] tissue is acceptable; fresh frozen tissue is preferred if available)

Accessible lesion representative of recurrent or metastatic breast cancer for biopsy

Type 1 specimen collection: Patients undergoing a clinically directed tissue biopsy or tissue collection who are willing to have additional specimens taken for research during the same procedure. Sites for tissue acquisition may include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, lung, brain, pleural fluid, and ascites as needed for routine clinical care
Type 2 specimen collection: Patients undergoing a tissue biopsy or tissue collection for research purposes only. Sites for tissue acquisition include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, pleural fluid, and ascites. Research directed lung biopsies and brain biopsies are not permitted. Procedures for tissue acquisition are restricted to those performed under local anesthesia or intravenous (IV) conscious sedation; biopsies that require general anesthesia are not permitted in this situation
Previous cytologic confirmation of malignant pleural effusion or ascites if that is the planned source of fresh specimen collection for study participation
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Ability to understand and the willingness to sign an informed consent document

Exclusion Criteria:

Concurrent disease or condition that in the opinion of the treating oncologist or the provider performing the biopsy procedure renders the patient inappropriate for study participation
Concurrent serious medical or psychiatric disorder that may interfere with the subject's safety during the biopsy or tissue collection procedure
Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
History of a serious or life-threatening allergic reaction to local anesthetics (e.g., lidocaine, xylocaine) used during a biopsy procedure
Pregnancy (due to the risk of conscious sedation or anesthesia to mother and fetus)
Any condition or laboratory finding that in the opinion of the treating oncologist or the provider performing the biopsy procedure would make participation in this protocol hazardous for the patient

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT03737695

Recruitment Status:

Recruiting

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

UCSF Medical Center-Mission Bay
San Francisco California, 94158, United States More Info
Amy N. DeLuca
Contact
415-353-7288
[email protected]
Amy N. DeLuca
Principal Investigator
MedStar Georgetown University Hospital
Washington District of Columbia, 20007, United States More Info
Claudine Isaacs
Contact
202-687-2219
[email protected]
Claudine Isaacs
Principal Investigator
University of Chicago Comprehensive Cancer Center
Chicago Illinois, 60637, United States More Info
Rita Nanda, M.D.
Contact
773-702-6149
[email protected]
Rita Nanda, M.D.
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center
Baltimore Maryland, 21287, United States More Info
Jessica Tao, M.D.
Contact
410-614-1361
[email protected]
Jessica Jelinek
Contact
410-614-1361
[email protected]
Jessica Tao, M.D.
Principal Investigator
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Nancy U. Lin
Contact
617-632-3000
[email protected]
Nancy U. Lin, M.D.
Principal Investigator
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Nancy McCullough
Contact
734-936-8538
[email protected]
Catherine H. Van Poznak
Principal Investigator
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Karthik V. Giridhar
Contact
855-776-0015
[email protected]
Karthik V. Giridhar, M.D.
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina, 27599, United States More Info
Kendalyn Stephens
Contact
919-962-5052
[email protected]
Lisa A. Carey
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Keiana K. Watkins
Contact
919-660-1278
[email protected]
Keiana K. Watkins
Principal Investigator
University of Pennsylvania/Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States More Info
Noah Goodman-Davis
Contact
215-898-5000
[email protected]
Angela M. DeMichele, M.D.
Principal Investigator
UPMC-Magee Womens Hospital
Pittsburgh Pennsylvania, 15213, United States More Info
Trisha N. Schneider
Contact
412-641-4706
Adam M. Brufsky
Principal Investigator
Vanderbilt Breast Center at One Hundred Oaks
Nashville Tennessee, 37204, United States More Info
Ben H. Park
Contact
800-811-8480
[email protected]
Ben H. Park
Principal Investigator
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States More Info
Shaveta Vinayak, M.D.
Contact
206-606-1890
[email protected]
Shaveta Vinayak, M.D.
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT03737695

Recruitment Status:

Recruiting

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider